• Malin-Theres Seffer, Gabriele Eden, Susanne Engelmann, and Jan T Kielstein.
• Nephrology | Rheumatology | Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Lower Saxony, Germany.
• BMJ Case Rep. 2020 Aug 24; 13 (8).

AbstractRemoval of bacteria from the blood by means of extracorporeal techniques has been attempted for decades. In late 2019, the European Union licensed the first ever haemoperfusion device for removal of bacteria from the blood. The active ingredient of Seraph 100 Microbind Affinity Blood Filter is ultrahigh molecular weight polyethylene beads with endpoint-attached heparin. Bacteria have been shown to bind to heparin as they would usually do to the heparan sulfate on the cell surface, thereby being removed from the blood stream. We describe the first case of a female chronic haemodialysis patient in which this device was clinically used for a Staphylococcus aureus infection that persisted for 4 days despite antibiotic therapy. After a single treatment, the bacterial load decreased and the blood cultures at the end of a 4 hour haemoperfusion exhibited no bacterial growth.© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

19 keywords...

hide…